Literature DB >> 7772616

Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs.

K Ikeguchi1, A Kuroda.   

Abstract

We evaluated the effects of mianserin, a relatively selective 5-HT2 receptor antagonist, on symptoms related to drug-induced psychosis in patients with Parkinson's disease (PD). A total of 12 patients with PD who had developed drug-induced psychosis showed delirium (DSM-III-R criteria; n = 10) and pure visual hallucinations (n = 2). The antiparkinsonian drugs involved in the drug-induced psychosis were L-DOPA/carbidopa, bromocriptine, trihexyphenidyl, and amantadine. They received mianserin (mean 36.7 mg, range 20-60 mg) given orally for 8 weeks. Complete relief or marked improvement in psychotic symptoms was noted in 8 patients, moderate improvement in 2 patients, and no effect in 2 patients. The parkinsonian disability also decreased slightly in 8 patients. These results suggest that serotonin antagonism at 5-HT2 receptors may not only play an important role in the treatment of drug-induced psychosis in PD, but may also ameliorate the symptoms of parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772616     DOI: 10.1007/bf02190411

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  27 in total

1.  Fluoxetine and extrapyramidal side effects.

Authors: 
Journal:  Am J Psychiatry       Date:  1989-10       Impact factor: 18.112

2.  A symptom rating scale for delirium.

Authors:  P T Trzepacz; R W Baker; J Greenhouse
Journal:  Psychiatry Res       Date:  1988-01       Impact factor: 3.222

3.  A new rating scale for dementia syndromes.

Authors:  C G Gottfries; G Bråne; G Steen
Journal:  Gerontology       Date:  1982       Impact factor: 5.140

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

Authors:  E Scholz; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

6.  Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.

Authors:  R A Glennon; R Young; J A Rosecrans
Journal:  Eur J Pharmacol       Date:  1983-07-22       Impact factor: 4.432

7.  Confusion, dementia and anticholinergics in Parkinson's disease.

Authors:  Y de Smet; M Ruberg; M Serdaru; B Dubois; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

8.  Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances.

Authors:  J Lehmann
Journal:  Acta Med Scand       Date:  1973

9.  Effects of ritanserin on sleep disturbances of dysthymic patients.

Authors:  T Paiva; F Arriaga; A Wauquier; E Lara; R Largo; J N Leitao
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.

Authors:  R A Glennon; M Titeler; J D McKenney
Journal:  Life Sci       Date:  1984-12-17       Impact factor: 5.037

View more
  14 in total

1.  A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Authors:  Kimberly E Vanover; Adrienne J Betz; Suzanne M Weber; Francesco Bibbiani; Aiste Kielaite; David M Weiner; Robert E Davis; Thomas N Chase; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

Review 2.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Comments and reply on Ikeguchi and Kuroda: Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs.

Authors:  J H Friedman; K Ikeguchi; A Kuroda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 5.  Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.

Authors:  P De Deurwaerdère; M Lagière; M Bosc; S Navailles
Journal:  Exp Brain Res       Date:  2013-04-25       Impact factor: 1.972

Review 6.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 7.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

8.  The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.

Authors:  M Lagière; S Navailles; L Mignon; A Roumegous; M-F Chesselet; P De Deurwaerdère
Journal:  Exp Brain Res       Date:  2013-03-28       Impact factor: 1.972

Review 9.  Management of non-motor complications in Parkinson's disease.

Authors:  Ken-ichi Fujimoto
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

10.  Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.

Authors:  Sanjay Kasture; Silvia Pontis; Annalisa Pinna; Nicoletta Schintu; Liliana Spina; Rosanna Longoni; Nicola Simola; Mauro Ballero; Micaela Morelli
Journal:  Neurotox Res       Date:  2009-02-20       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.